Molecular analyses of diagnosis and disease progression samples from 54 FLT3-ITD–positive, relapse/refractory patients treated with midostaurin addition (left) compared with those from 21 FLT3-ITD–positive, relapse/refractory patients not exposed to midostaurin (right). TKD, tyrosine kinase domain. Figure prepared by David G. J. Cucchi (created with BioRender.com).